CU20210023A7 - Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 - Google Patents

Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4

Info

Publication number
CU20210023A7
CU20210023A7 CU2021000023A CU20210023A CU20210023A7 CU 20210023 A7 CU20210023 A7 CU 20210023A7 CU 2021000023 A CU2021000023 A CU 2021000023A CU 20210023 A CU20210023 A CU 20210023A CU 20210023 A7 CU20210023 A7 CU 20210023A7
Authority
CU
Cuba
Prior art keywords
phosphodiesterase
oxaborolan
pyridinyl
inhibitors
substitute phenyl
Prior art date
Application number
CU2021000023A
Other languages
English (en)
Inventor
Tsutomu Akama
David Clive Blakemore
Robert Toms Jacobs
Peter Jones
David Christopher Limburg
Martins Sunday Oderinde
Matthew Alexander Perry
Jacob John Plattner
Joseph Walter Strohbach
Rubben Federico Torella
Thean Yeow Yeoh
Yasheen Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20210023(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CU20210023A7 publication Critical patent/CU20210023A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>La presente invención se refiere a compuestos inhibidores de la fosfodiesterasa 4 de Fórmula (IA) o Fórmula (IB).</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmaceúticamente aceptable de los mismos, en los que R1, R2, R3, R4, R5, R6, R7,R9,R10, A1, A2 y p son como se define en el presente documento.</p>
CU2021000023A 2018-10-05 2019-10-01 Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 CU20210023A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741868P 2018-10-05 2018-10-05
US201962889599P 2019-08-21 2019-08-21
PCT/IB2019/058355 WO2020070651A1 (en) 2018-10-05 2019-10-01 Boron containing pde4 inhibitors

Publications (1)

Publication Number Publication Date
CU20210023A7 true CU20210023A7 (es) 2021-10-12

Family

ID=68136492

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000023A CU20210023A7 (es) 2018-10-05 2019-10-01 Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4

Country Status (30)

Country Link
US (3) US10946031B2 (es)
EP (1) EP3861001B1 (es)
JP (1) JP7048823B2 (es)
KR (1) KR102576125B1 (es)
CN (1) CN113166177B (es)
AU (1) AU2019351960B2 (es)
BR (1) BR112021005870B1 (es)
CA (1) CA3114702C (es)
CL (1) CL2021000843A1 (es)
CO (1) CO2021003928A2 (es)
CR (1) CR20210163A (es)
CU (1) CU20210023A7 (es)
DK (1) DK3861001T3 (es)
DO (1) DOP2021000055A (es)
EC (1) ECSP21023404A (es)
ES (1) ES2974208T3 (es)
FI (1) FI3861001T3 (es)
GE (2) GEP20227442B (es)
IL (1) IL282083B2 (es)
MA (1) MA53808A (es)
MX (1) MX2021003871A (es)
NI (1) NI202100020A (es)
PE (1) PE20211546A1 (es)
PH (1) PH12021550743A1 (es)
PY (1) PY1983118A (es)
SG (1) SG11202102674RA (es)
TW (1) TWI764052B (es)
UY (1) UY38400A (es)
WO (1) WO2020070651A1 (es)
ZA (1) ZA202101822B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100719YA (en) 2018-07-24 2021-02-25 Taiho Pharmaceutical Co Ltd Heterobicyclic compounds for inhibiting the activity of shp2
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
JP2023538362A (ja) * 2020-08-20 2023-09-07 ファイザー・インク 1(r)-4-(5-(4-メトキシ-3-プロポキシフェニル)ピリジン-3-イル)-1,2-オキサボロラン-2-オールの安定な局所製剤
EP4204012A1 (en) 2020-08-31 2023-07-05 Pfizer Inc. Methods of protecting rna
MX2023007579A (es) * 2020-12-25 2023-07-06 Reistone Biopharma Company Ltd Derivado de borato y usos del mismo.
TW202404610A (zh) * 2022-06-24 2024-02-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的結晶、其製備方法及用途
TW202408483A (zh) * 2022-06-24 2024-03-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的可藥用鹽、其結晶形式及用途
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
JP5038912B2 (ja) * 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ,インコーポレイテッド ホウ素含有小分子
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP5745279B2 (ja) 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ,インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
BRPI0908565A2 (pt) * 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
WO2012067663A1 (en) * 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
CN103857289A (zh) 2011-10-07 2014-06-11 先正达参股股份有限公司 用于保护有用植物或植物繁殖材料的方法
PL2912019T3 (pl) * 2012-10-25 2021-11-02 Tetra Discovery Partners Llc Heteroarylowe inhibitory pde4
EP2752196A1 (en) 2013-01-03 2014-07-09 Université Bordeaux Segalen Selective nox-1 inhibitor peptides and uses thereof
DK2950644T3 (en) 2013-01-30 2017-09-04 Agrofresh Inc USE OF BENZOXABOROLS AS VOLATIVE ANTIMICROBIAL AGENTS IN MEAT, PLANTS OR PARTS
WO2014147009A1 (en) 2013-03-18 2014-09-25 Syngenta Participations Ag Novel microbiocides
AU2014202928B1 (en) 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN112088157B (zh) 2017-12-22 2023-12-26 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物

Also Published As

Publication number Publication date
US20230148402A1 (en) 2023-05-11
DK3861001T3 (da) 2024-01-15
CA3114702A1 (en) 2020-04-09
TWI764052B (zh) 2022-05-11
KR102576125B1 (ko) 2023-09-08
BR112021005870B1 (pt) 2024-01-09
SG11202102674RA (en) 2021-04-29
MA53808A (fr) 2022-01-12
GEP20227442B (en) 2022-11-25
CA3114702C (en) 2023-08-08
PH12021550743A1 (en) 2021-10-11
DOP2021000055A (es) 2021-05-16
CO2021003928A2 (es) 2021-04-19
US20200108083A1 (en) 2020-04-09
IL282083B1 (en) 2025-01-01
US20210069219A1 (en) 2021-03-11
PE20211546A1 (es) 2021-08-16
EP3861001A1 (en) 2021-08-11
WO2020070651A1 (en) 2020-04-09
EP3861001B1 (en) 2023-12-13
IL282083A (en) 2021-05-31
CR20210163A (es) 2021-06-24
KR20210068532A (ko) 2021-06-09
BR112021005870A2 (pt) 2021-07-27
UY38400A (es) 2020-04-30
MX2021003871A (es) 2021-05-27
AU2019351960B2 (en) 2022-07-28
IL282083B2 (en) 2025-05-01
CL2021000843A1 (es) 2021-09-10
JP2021534222A (ja) 2021-12-09
AU2019351960A1 (en) 2021-04-29
FI3861001T3 (fi) 2024-01-03
ECSP21023404A (es) 2021-05-31
ES2974208T3 (es) 2024-06-26
NI202100020A (es) 2021-08-24
US10946031B2 (en) 2021-03-16
CN113166177B (zh) 2024-09-03
JP7048823B2 (ja) 2022-04-05
US11559538B2 (en) 2023-01-24
GEAP202215599A (en) 2022-08-10
TW202027755A (zh) 2020-08-01
PY1983118A (es) 2021-07-15
CN113166177A (zh) 2021-07-23
ZA202101822B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
UY38057A (es) Inhibidores de sarcómero cardíaco
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CR20140413A (es) Inhibidores de serina/treonina cinasa
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
CL2021001461A1 (es) Moduladores de trex1
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR086482A1 (es) Inhibidores de aldosterona sintasa
MX368178B (es) Compuestos de ácido dimetilbenzoico.
CL2020002550A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.
ECSP13012363A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
CU20110101A7 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
MX2019000103A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.